Advances in Diagnosis &amp; Imaging Impacting Cancer Treatment

Prof. Eric Raymond Oncologie Medicale

This document provides a summary of a presentation on molecular signaling pathways and their implications in gynecologic oncology. The presentation discusses several key topics: 1. Hallmarks of cancer development including activation of oncogenes, inactivation of tumor suppressor genes, DNA damage repair pathways, and apoptotic factors. 2. Major signaling pathways in cancer like MAPK, PI3K/AKT/mTOR, Wnt, TGF-beta, and their roles. 3. Targeted therapy approaches for gynecologic cancers including monoclonal antibodies ("-mabs"), small molecule inhibitors ("-nibs"), drugs targeting DNA repair ("-ribs"), and immunotherapies. 4. Gen

Molecular targets and their significance in the management

deepak2006

New Targets & New Drugs in Hepatocellular carcinoma

This document summarizes a presentation on new targets and agents for hepatocellular carcinoma. It discusses several new targets including VEGFR, PDGFR, c-MET, FGFR4, TGF-β, and PD-1/PDL1 that are being investigated with new agents. Regorafenib and nivolumab are highlighted as agents that have shown survival benefits in late stage trials for HCC. Other agents discussed include tepotinib as a c-MET inhibitor and galunisertib as a TGF-β inhibitor. Combination approaches are also a focus, including using PD-L1 inhibitors with other agents and combining galunisertib with sorafenib.

Medicon 2016 presentation

madurai

Newer diagnostic tools in oncology such as liquid biopsies provide non-invasive approaches to diagnosing and monitoring cancer. Liquid biopsies analyze biomarkers found in bodily fluids and can detect circulating tumor cells, circulating tumor DNA, RNA, and exosomes shed by tumors into the bloodstream. These liquid biomarkers offer advantages over traditional tissue biopsies by being less invasive, able to capture the heterogeneity of tumors, and allow for real-time monitoring of treatment response and disease progression. Emerging technologies now allow liquid biopsies to provide genomic information that can help classify and treat cancers based on their molecular profiles rather than the organ or tissue of origin.

Overexpression of YAP 1 contributes to progressive features and poor prognosi...

HTAi 2015 - Cost-effectiveness analysis of bevacizumab and cetuximab in advan...

REBRATSoficial

This document summarizes a cost-effectiveness analysis of treatment strategies for metastatic colorectal cancer in Brazil. It finds that adding monoclonal antibodies like bevacizumab and cetuximab to chemotherapy improves survival but that the strategies are not cost-effective in Brazil's public health system as the cost per life year gained is over the hypothetical threshold of 3 times GDP per capita. The analysis uses a Markov model to compare costs and outcomes of 3 treatment sequences over a lifetime, finding that chemotherapy alone without antibodies has the best cost-effectiveness profile.

2014 CFTCC Annual Symposium: Circulating Tumor Cells: Linking Analysis to Sur...

CFTCC

The document discusses circulating tumor cells (CTCs) and their clinical applications. It summarizes the work of Brian Kirby's research group, which works at the interface of microfluidics, microtechnology, and cellular analysis. The group has developed a technique called GEDI (Geometrically Enhanced Differential Immunocapture) to isolate CTCs from blood samples. GEDI leverages fluid mechanical design and size-dependent interactions to maximize capture of rare CTCs while eliminating leukocytes. The group has used captured CTCs from castrate-resistant prostate cancer patients to functionally evaluate drug responses by examining markers like tubulin bundling and nuclear accumulation of the androgen receptor. They are currently conducting the

Dr Dinah Parums. The Role of the Pathologist in Targeted Therapy and Personal...

Dinah Parums

This document discusses the role of pathologists in targeted cancer therapy and personalized medicine. It outlines the key components of a pathology capability including tissue acquisition, processing, staining, and molecular analysis techniques like immunohistochemistry and in situ hybridization. The document emphasizes how pathologists can help validate drug targets and biomarkers through localization of proteins and nucleic acids in tissues. It also discusses challenges like antibody characterization and validation, and the importance of standardizing immunohistochemistry methods for clinical trials and companion diagnostics. Overall, the document illustrates how pathology informs targeted cancer treatment by identifying biomarkers that can predict a patient's response to specific therapies.

Integrative Cancer - New theories and Advances in Treatment From Hippocrates ...

Sheldon Stein

20160219 Livia Marcato - Cell Free DNA and Liquid Biopsy

Roberto Scarafia

CTC Methods in comparison

Peter Pachmann

Maintrac liquid biopsy allows quantitative detection of circulating tumor cells without fixation, isolation, or enrichment. It uses fluorochrome-labeled antibody targeting EpCAM antigen on circulating tumor cells. In contrast, Cellsearch uses fixation and enrichment procedures that lead to loss of cells and antigenicity, resulting in dead cells. Comparison of the two methods using the same blood sample from a patient showed Maintrac detected more total events and circulating tumor cells than Cellsearch. Other CTC detection technologies have limitations such as relying too heavily on EpCAM expression or assuming CTCs are larger than blood cells. Cell-free tumor DNA analysis has problems like representing destroyed cells and additional mutations from DNA degradation.

Integrative Analysis of Gene Expression and Promoter Methylation during Repro...

Y-h Taguchi

Portec 4a

(1) The document summarizes the PORTEC 4A trial, which aims to evaluate molecular risk profiling to guide adjuvant treatment decisions in early-stage endometrial cancer. (2) The trial compares adjuvant vaginal brachytherapy, the current standard, to a molecular profiling-based approach that may recommend observation, brachytherapy, or pelvic radiation. (3) Based on previous studies, it is estimated that 50-55% of patients will be low risk and need only observation, 40% intermediate risk requiring brachytherapy, and 5-10% high risk needing pelvic radiation. The goal is to reduce overtreatment while maintaining local control.

Estado actual de terapia sistémica en cáncer renal metastásico

Mauricio Lema

This document discusses the current management of metastatic renal cell carcinoma (mRCC). It provides an overview of targeted therapies for mRCC including tyrosine kinase inhibitors (TKIs) such as sunitinib, pazopanib, and cabozantinib that target the VEGF pathway. Clinical trial results are presented comparing TKIs in first-line mRCC. Active surveillance is also discussed as a treatment option for select asymptomatic or minimally symptomatic mRCC patients. Toxicities of TKIs like fatigue, diarrhea and hand-foot syndrome are reviewed along with their negative impact on quality of life.

1471 2407-13-363

Recently, a phase II clinical trial in hepatocellular carcinoma (HCC) has suggested that the combination of sorafenib and 5-fluorouracil (5-FU) is feasible and side effects are manageable. However, preclinical experimental data explaining the interaction mechanism(s) are lacking. Our objective is to investigate the anticancer efficacy and mechanism of combined sorafenib and 5-FU therapy in vitro in HCC cell lines MHCC97H and SMMC-7721.

Clinical and experimental studies regarding the expression and diagnostic val...

Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a multifunctional Ig-like cell adhesion molecule that has a wide range of biological functions. According to previous reports, serum CEACAM1 is dysregulated in different malignant tumours and associated with tumour progression. However, the serum CEACAM1 expression in nonsmall-cell lung carcinomas (NSCLC) is unclear. The different expression ratio of CEACAM1-S and CEACAM1-L isoform has seldom been investigated in NSCLC. This research is intended to study the serum CEACAM1 and the ratio of CEACAM1-S/L isoforms in NSCLC.

Outsourcing

clinicaloutsourcing

Bonnie Mangold presented on Novartis' new strategic sourcing model of partnering with clinical research organizations (CROs). The model aims to bring in new capabilities and opportunities through expanded CRO partnerships. It involves integrating CRO teams into program teams, benchmarking performance, and shifting some activities traditionally viewed as core competencies to CROs. Initial pilots showed benefits like access to expertise and improved development times, though internal barriers had to be overcome. Metrics were used to measure success and identify areas for further improvement and learning.

HealthTRx-Sales-Sheet-NEW

Constance Cranford

This document provides a list of limited distribution medications across various therapeutic areas including alpha-1 antitrypsin deficiency, bleeding disorders, dermatology, gastroenterology, growth hormone, hereditary angioedema, hepatitis C, HIV/AIDS, immunoglobulin therapy, oncology, ophthalmology, respiratory syncytial virus, and rheumatology. It then describes HealthTRx as a specialty pharmacy network that can help clients and patients find the right pharmacy to meet their specialty healthcare needs and access customized solutions and support programs.

What's hot

Application of immunotherapy therapeutics in prostate adenocarcinoma slides

Jamie Cooper

Chapter 2.3 tumor biomarkers and vascular access

Nilesh Kucha

Clinical value of circulating tumor cells in metastatic breast cancer

Nikos Xenidis

Cco metastatic colorectal_cancer_cases_slides

Adonis Guancia

Targetted therapies in GYn Oncolgy

Prof. Eric Raymond Oncologie Medicale

Molecular targets and their significance in the management

deepak2006

New Targets & New Drugs in Hepatocellular carcinoma

Medicon 2016 presentation

madurai

Overexpression of YAP 1 contributes to progressive features and poor prognosi...

HTAi 2015 - Cost-effectiveness analysis of bevacizumab and cetuximab in advan...

REBRATSoficial

2014 CFTCC Annual Symposium: Circulating Tumor Cells: Linking Analysis to Sur...

CFTCC

Dr Dinah Parums. The Role of the Pathologist in Targeted Therapy and Personal...

Dinah Parums

Integrative Cancer - New theories and Advances in Treatment From Hippocrates ...

Sheldon Stein

20160219 Livia Marcato - Cell Free DNA and Liquid Biopsy

Roberto Scarafia

CTC Methods in comparison

Peter Pachmann

Integrative Analysis of Gene Expression and Promoter Methylation during Repro...

Y-h Taguchi

Portec 4a

Estado actual de terapia sistémica en cáncer renal metastásico

Mauricio Lema

1471 2407-13-363

Clinical and experimental studies regarding the expression and diagnostic val...

Dana-Farber Cancer Institute

What's hot (20)

Application of immunotherapy therapeutics in prostate adenocarcinoma slides

Chapter 2.3 tumor biomarkers and vascular access

Clinical value of circulating tumor cells in metastatic breast cancer

Cco metastatic colorectal_cancer_cases_slides

Targetted therapies in GYn Oncolgy

Molecular targets and their significance in the management

New Targets & New Drugs in Hepatocellular carcinoma

Medicon 2016 presentation

Overexpression of YAP 1 contributes to progressive features and poor prognosi...

HTAi 2015 - Cost-effectiveness analysis of bevacizumab and cetuximab in advan...

2014 CFTCC Annual Symposium: Circulating Tumor Cells: Linking Analysis to Sur...

Dr Dinah Parums. The Role of the Pathologist in Targeted Therapy and Personal...

Integrative Cancer - New theories and Advances in Treatment From Hippocrates ...

20160219 Livia Marcato - Cell Free DNA and Liquid Biopsy

CTC Methods in comparison

Integrative Analysis of Gene Expression and Promoter Methylation during Repro...

Portec 4a

Estado actual de terapia sistémica en cáncer renal metastásico

1471 2407-13-363

Clinical and experimental studies regarding the expression and diagnostic val...

Viewers also liked

Outsourcing

clinicaloutsourcing

HealthTRx-Sales-Sheet-NEW

Constance Cranford

Falta de atendimento focado - Gilberto Amorim

Oncoguia

O documento discute as deficiências no tratamento do câncer de mama e pulmão no Brasil, especialmente no SUS. Há atrasos significativos no acesso a tratamentos inovadores como trastuzumabe e terapias-alvo, resultando em centenas de mortes precoces a cada ano. O documento defende parcerias entre governo e indústria para reduzir custos, assim como a implementação urgente de políticas para equalizar o acesso entre SUS e planos de saúde.

Nanoparticles for magnetic resonance imaging

Alex Chris

This document discusses the use of various types of nanoparticles for molecular imaging applications such as magnetic resonance imaging (MRI) and computer tomography (CT). It describes how gold nanoparticles, quantum dots, iron oxide nanoparticles, carbon nanotubes, dendrimers, and other nanoparticles are being investigated and developed as contrast agents for molecular imaging due to their tunable properties and potential for functionalization and targeted delivery. For example, one study demonstrated how antibody-conjugated gold nanorods could selectively target and image squamous cell carcinoma tumors using CT. Overall, the controlled properties of engineered nanoparticles show promise for improving molecular imaging techniques.

Final 27 aug seminr

Pooja Goswami

The document summarizes tissue regeneration and fibrosis. It covers the normal wound healing process and definitions of regeneration versus repair. It discusses stem cells, growth factors, signaling pathways, extracellular matrix components and cell-matrix interactions that are important for regeneration. Fibrosis occurs when there is excessive or uncontrolled deposition of extracellular matrix proteins like collagen. Maintaining the proper balance between deposition and degradation of extracellular matrix components is key to avoiding fibrosis and allowing normal tissue regeneration.

Gold nanoparticles against cancer

Arunaksha Chakraborty

Molecular Imaging

gumccomm

The Molecular Imaging Laboratory at Howard University provides state-of-the-art imaging equipment including high resolution MRI systems for small animal and clinical research. The lab aims to train students and foster multidisciplinary research using imaging to study disease processes and investigate new treatments. Areas of research include in vivo MRI and optical imaging of disease models in small animals, as well as molecular imaging of biological processes and developing new imaging probes and nanoparticles.

David wong advances in oral cancer prevention - applications in public health

Mukul Lal

The document summarizes David Wong's presentation on using saliva for disease diagnostics at the National Oral Health Conference on May 1, 2007. The presentation discussed developing saliva-based biomarkers for oral cancer detection using proteomic and genomic analysis of the human salivary proteome. It provided an example of detecting oral cancer using 4 RNA biomarkers in saliva with a sensitivity of 91% and specificity of 91%. The presentation envisioned future handheld devices for rapid saliva testing to detect various diseases like diabetes and cancers.

Funed

Alfob

A Funed é o laboratório farmacêutico oficial do estado de Minas Gerais, destacando-se pela produção exclusiva de medicamentos como a Talidomida e a vacina contra meningite C. Além disso, a Funed possui laboratórios de pesquisa, produz soros antipeçonhentos e participa de parcerias para o desenvolvimento de novos medicamentos. A Funed também atua como laboratório central de saúde pública, realizando diagnósticos e análises.

UCLA SOD Annual Report_spread_11.5.15

Brianna Aldrich

The 2014-2015 annual report from the UCLA School of Dentistry summarizes the year's educational activities. It highlights the graduation of the Class of 2015 and their postgraduate plans. It also introduces the incoming Class of 2018 and recognizes donors who support students through scholarships. Additionally, it describes programs led by students that provide dental care to veterans and foster youth, as well as leadership development initiatives for students.

Cierre del Simposio Novartis de Biología Molecular e Investigación en Oncología

Mauricio Lema

Viewers also liked (11)

Outsourcing

HealthTRx-Sales-Sheet-NEW

Falta de atendimento focado - Gilberto Amorim

Nanoparticles for magnetic resonance imaging

Final 27 aug seminr

Gold nanoparticles against cancer

Molecular Imaging

David wong advances in oral cancer prevention - applications in public health

Funed

UCLA SOD Annual Report_spread_11.5.15

Cierre del Simposio Novartis de Biología Molecular e Investigación en Oncología

Similar to Advances in Diagnosis & Imaging Impacting Cancer Treatment

Question of Quality Conference 2016 - Personalized Cancer Medicine

HCA Healthcare UK

This document summarizes a presentation on personalized cancer medicine. It discusses: 1. A brief history of precision oncology, from identifying the Philadelphia chromosome in 1960 to recent advances in immunotherapy. 2. The concept of driver mutations that directly or indirectly confer growth advantages to cancer cells and have clinical implications for diagnosis, prognosis, or targeted therapies. 3. How next-generation sequencing can best identify all four classes of genomic alterations that drive tumor growth by sequencing both DNA and RNA. 4. Some case histories where genomic profiling identified targetable alterations and patients benefited from matched targeted therapies. 5. Concluding thoughts on the complexity of the cancer genome and how comprehensive genomic profiling is enabling evidence-based

#HCAQofQ Tariq Mughal

Rebecca Pullen

Tariq Mughal discusses personalized cancer medicine and highlights some key points: 1. Precision medicine has evolved greatly over the past few decades from basic cytogenetics and hormone therapies to comprehensive genomic profiling and immunotherapy. Targeted therapies are revolutionizing cancer treatment. 2. Driver mutations directly or indirectly confer a growth advantage to cancer cells and have clinical implications for diagnosis, prognosis, and targeted therapies. Comprehensive genomic profiling using next-generation sequencing can best identify all classes of driver mutations. 3. Case histories demonstrate how genomic profiling can identify targetable genomic alterations like ERBB2 mutations, ALK fusions, and FBXW7 mutations and guide treatment with targeted therapies, often with dramatic responses

SHARE: Report Back from Annual Meeting of American Association of Cancer Rese...

bkling

principles_of_oncology.ppt

akamkhalidmohammed

This document provides an overview of principles of oncology including the etiology, pathology, classification, staging, and management of cancer. It discusses that cancer develops from altered cell growth mechanisms and is a multistage genetically regulated process. Tumors are classified based on their topographic site, histology, and anatomic extent (staging). Staging involves assessing the tumor size (T), lymph node involvement (N), and distant metastasis (M). A multidisciplinary approach is used in cancer management, which may involve surgery, radiation, chemotherapy, and other therapies, with the main goals being cure, prolonged survival, or symptom relief.

What's New in Research for ER+ Metastatic Breast Cancer

Nikhil Wagle, MD, discusses new research and how it is leading the way toward improved treatments for ER+ metastatic breast cancer. Wagle is a physician with the Breast Oncology Program in the Susan F. Smith Center for Women's Cancers at Dana-Farber. He is also a researcher affiliated with Dana-Farber and the Broad Institute. This presentation was originally given as part of the Metastatic Breast Cancer Forum, held on Oct. 17, 2015 at Dana-Farber Cancer Institute in Boston, Mass.

Stage IIB carcinoma of the cervix that is associated with pelvic kidney: Athe...

MedicineAndHealth14

The document discusses potential applications of peptides as biotherapeutic tools, including: 1) Using opioid growth factor (OGF) to treat pancreatic and head and neck cancers by inhibiting cancer growth. 2) Developing antibodies and ELISA kits to detect OGF receptors to aid in diagnosis and screening for cancers. 3) Applying the opioid antagonist naltrexone to accelerate wound healing in conditions like diabetic wounds. Clinical trials and research partnerships are underway or planned for these applications.

PEPTIDES AS BIOTHERAPEUTIC TOOLS PEPTIDES AS BIOTHERAPEUTIC TOOLS

MedicineAndHealth14

The document discusses potential biotherapeutic applications of opioid growth factor (OGF) and its receptor (OGFr) for treating several cancers and diabetic wounds. It outlines clinical trials and milestones achieved using OGF to treat pancreatic and head and neck cancers. It also discusses using the opioid antagonist naltrexone to accelerate wound healing in diabetes. Potential market sizes are provided for pancreatic cancer, head and neck cancer, and diabetic wound healing applications.

Cancer Survivorship Challenges and Opportunities

GaynorOncology

This document discusses cancer survivorship challenges and opportunities. It provides statistics on cancer survivors such as over 60% being over age 65 and the most common cancer sites being breast, prostate, and colorectal. It then discusses trends in improved 5-year survival rates for many cancer sites from 1975-2003. The document outlines goals for cancer survivors including monitoring biomarkers, maintaining wellness through lifestyle factors like nutrition and exercise, and becoming active participants in their care. Biomarkers discussed include fasting insulin levels, IGF-1, and drug metabolism biomarkers. The roles of lifestyle factors like meditation, yoga, exercise, music, spirituality, and nutrition including soy and vitamin D are also summarized.

Precision Medicine: Opportunities and Challenges for Clinical Trials

Medpace

The momentum and muscle behind "finding the right drug for the right patient at the right dose" has further escalated with President Barack Obama’s announcement of a $215 million dollar Precision Medicine Initiative earlier this year. In this webinar, Dr. Frank Smith will explore advances in precision medicine and how it is affecting clinical research. As a pediatric hematologist/oncologist, he will use his extensive clinical and research background as a backdrop for the discussion. Topics will include: The evolution of "personalized medicine" to "precision medicine" How state-of-the-art molecular biology is creating new diagnostic and prognostic strategies How these new strategies are helping inform the design of clinical trials Case study: How precision medicine is improving clinical trials in hematology and oncology

Development of Novel Targeted Drugs: Which Target? by Eric Raymond

Prof. Eric Raymond Oncologie Medicale

Breast Cancer Treatment: Where we are, Where we're going - April 24th, 2018

Summit Health

This document summarizes a presentation on breast cancer treatment. It discusses: 1) The current state of breast cancer treatment including molecular classification, adjuvant therapies, neoadjuvant therapies, and treatments for metastatic disease. 2) Surgical options for breast cancer including lumpectomy, mastectomy, and breast reconstruction techniques. 3) Radiation therapy techniques including reducing heart dose using deep inspiration breath hold and shorter treatment schedules.

August 2019 - Recurrence: What now?

Fight Colorectal Cancer

Cu dota igcc slides 6 2-15

Audrey Choi, MD

This study aims to evaluate a novel radioimmunoconjugate, 64Cu-DOTA-Trastuzumab, for assessing HER2 expression in gastric cancer patients via PET/CT imaging. The study hypothesizes that 64Cu-DOTA-Trastuzumab PET may better localize HER2-overexpressing gastric tumors by overcoming tumor heterogeneity, and more accurately measure functional HER2 expression compared to current IHC and FISH methods. The clinical trial will compare 64Cu uptake measured by PET/CT to IHC and FISH results from surgical specimens to determine if the novel imaging agent improves detection of patients eligible for trastuzumab therapy.

Understanding Uterine Cancer Treatment Options

bkling

Russell

Nic Russell

1) Identification of gene signatures and biomarkers in breast cancer, such as the Notch pathway, may help develop targeted therapies for different subtypes. 2) The Notch pathway promotes breast cancer stem cell growth and inhibiting it with gamma secretase inhibitors reduces cancer cell proliferation and invasion. 3) PARP inhibitors show promise as a targeted treatment for triple negative breast cancer associated with BRCA mutations by exploiting "synthetic lethality" - inhibiting both BRCA and PARP pathways kills cancer cells. Large-scale identification of PARP substrates may help identify predictive markers for effective PARP inhibitor therapy.

Prostate PIL.pptx

Hinduja Healthcare Surgical

Νικόλαος Τσούλος, MedTech Conference 2021

Starttech Ventures

The State of Lung Cancer Research by Manahil khanam durrani.pptx

The Women University Multan

Lung cancer is the most common cancer in males and second most common in females after breast cancer. it is the third most commonly diagnosed and leading cause of cancer death in Pakistan, with an estimated 6,800 (4.6%) new cases and 6,013 (5.9%) deaths occurring in 2012 We have compared our data with the international statistics to see where do we stand. In Pakistan, we do not have a valid central cancer registry at present which can provide a true picture of lung cancer. This calls for an urgent need to formulate a valid central cancer registry in the country in association with the local bodies.

Rare Cancers: The Time to Act is Now

Canadian Cancer Survivor Network

Rare cancers account for approximately 22% of all cancer diagnoses and 24% of all cancer cases. While individual rare cancers are individually rare, collectively they are not uncommon. Recent advances in genetic and genomic testing have enabled more precise diagnosis and targeting of treatments for rare cancers based on genetic abnormalities. However, rare cancers still face challenges including a lack of information and support organizations, limited clinical trials and reimbursement options, and difficulties in drug development and regulatory approval due to small patient populations.

Dissertation topics on cellular basics of cancer and therapeutics - Pubrica

Pubrica

• Researching cancer and its therapeutics is an important tool for cancer studies and medical writing services. • The important topics to be covered while writing a thesis for cancer and its therapeutics are discussed in scientific medical writing. • Pubrica is here to help with the easy scientific medical writingabout cancer research and its therapeutics. Full Information: https://bit.ly/3llZgmV Reference: https://pubrica.com/services/physician-writing-services/ Why Pubrica? When you order our services, we promise you the following – Plagiarism free, always on Time, outstanding customer support, written to Standard, Unlimited Revisions support and High-quality Subject Matter Experts. Contact us : Web: https://pubrica.com/ Blog: https://pubrica.com/academy/ Email: sales@pubrica.com WhatsApp : +91 9884350006 United Kingdom: +44- 74248 10299

Similar to Advances in Diagnosis & Imaging Impacting Cancer Treatment (20)

Question of Quality Conference 2016 - Personalized Cancer Medicine

#HCAQofQ Tariq Mughal

SHARE: Report Back from Annual Meeting of American Association of Cancer Rese...

principles_of_oncology.ppt

What's New in Research for ER+ Metastatic Breast Cancer

Stage IIB carcinoma of the cervix that is associated with pelvic kidney: Athe...

PEPTIDES AS BIOTHERAPEUTIC TOOLS PEPTIDES AS BIOTHERAPEUTIC TOOLS

Cancer Survivorship Challenges and Opportunities

Precision Medicine: Opportunities and Challenges for Clinical Trials

Development of Novel Targeted Drugs: Which Target? by Eric Raymond

Breast Cancer Treatment: Where we are, Where we're going - April 24th, 2018

August 2019 - Recurrence: What now?

Cu dota igcc slides 6 2-15

Understanding Uterine Cancer Treatment Options

Russell

Prostate PIL.pptx

Νικόλαος Τσούλος, MedTech Conference 2021

The State of Lung Cancer Research by Manahil khanam durrani.pptx

Rare Cancers: The Time to Act is Now

Dissertation topics on cellular basics of cancer and therapeutics - Pubrica

More from Dr.Harsha Doddihal

Krupanandhi college magazine 20th may 2016

Trends & Developments in Healthcare

"Expressions 2014"- Magazine of Krupanidhi College of Pharmacy

HTA Uncovered february 2014

The document discusses the potential impact of accountable care organizations (ACOs) on biopharmaceutical reimbursement and access in the United States based on a survey of medical directors. Key points: - The survey found that medical directors anticipate ACOs will increase emphasis on clinical pathways and provider value scrutiny. They also expect higher thresholds for acceptance of new technologies and potential changes to contracting terms. - This suggests manufacturers need to understand how ACO models may impact technology acceptance and uptake. They should consider overall relative value, fit within care pathways, and the increasing role of providers as gatekeepers to access. - Background information provides context on the rise of ACOs in the US healthcare system and how they differ from

Why did i get cancer

Hacking the brain sleep exercise

Oncology clinical trials regulations & benefits